LOURDES M VARELA

Dr. LOURDES M VARELA

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2013 in British Journal of Pharmacology
Verified
Journal Article
Closed access
PDF file
ATA Tran-Dinh
A Tran-Dinh
DDD Diallo
D Diallo
SDS Delbosc
S Delbosc
LVLOURDES M VARELA
LOURDES M VARELA
QDQ B Dang
Q B Dang
OMOlivier Meilhac
Olivier Meilhac

1 June 2014 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
SLSergio Lopez
Sergio Lopez
BBBeatriz Bermudez
Beatriz Bermudez
Sergio Montserrat-De La PazSergio Montserrat-De La Paz
Sergio Montserrat-De La Paz
SJSara Jaramillo-Carmona
Sara Jaramillo-Carmona
LVLOURDES M VARELA
LOURDES M VARELA
FMFrancisco J.G. Muriana
Francisco J.G. Muriana

5 October 2010 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
SJSara Jaramillo-Carmona
Sara Jaramillo-Carmona
SLSergio Lopez
Sergio Lopez
LVLOURDES M VARELA
LOURDES M VARELA
María Rocío Rodríguez ArcosMaría Rocío Rodríguez Arcos
María Rocío Rodríguez Arcos
Ana Jimenez-AraujoAna Jimenez-Araujo
Ana Jimenez-Araujo
FMFrancisco J. G. Muriana
Francisco J. G. Muriana

29 November 2016 in Circulation
Verified
Journal Article
Closed access
PDF file
GVGemma Vilahur
Gemma Vilahur
MGManuel Gutiérrez
Manuel Gutiérrez
LCLaura Casani
Laura Casani
LVLOURDES M VARELA
LOURDES M VARELA
ACAntoni Capdevila
Antoni Capdevila
Lina BadimonLina Badimon
Lina Badimon
Background: The P2Y 12 receptor antagonist ticagrelor has been shown to be clinically superior to clopidogrel. Although the underlying mechanisms remain elusive, ticagrelor may exert off-target effects through adenosine-related mechanisms. We aimed to investigate whether ticagrelor reduces myocardial injury to a greater extent than clopidogrel after myocardial infarction (MI) at a similar level of platelet inhibition and to determine the underlying mechanisms. Methods: Pigs received the following before MI induction: (1) placebo-control; (2) a loading dose of clopidogrel (600 mg); (3) a loading dose of ticagrelor (180 mg); or (4) a loading dose of ticagrelor followed by an adenosine A1/A2-receptor antagonist [8-( p -sulfophenyl)theophylline, 4 mg/kg intravenous] to determine the potential contribution of adenosine in ticagrelor-related cardioprotection. Animals received the corresponding maintenance doses of the antiplatelet agents during the following 24 hours and underwent 3T-cardiac MRI analysis. Platelet inhibition was monitored by ADP-induced platelet aggregation. In the myocardium, we assessed the expression and activation of proteins known to modulate edema formation, including aquaporin-4 and AMP-activated protein kinase and its downstream effectors CD36 and endothelial nitric oxide synthase and cyclooxygenase-2 activity. Results: Clopidogrel and ticagrelor exerted a high and consistent antiplatelet effect (68.2% and 62.2% of platelet inhibition, respectively, on challenge with 20 μmol/L ADP) that persisted up to 24 hours post-MI ( P <0.05). All groups showed comparable myocardial area-at-risk and cardiac worsening after MI induction. 3T-Cardiac MRI analysis revealed that clopidogrel- and ticagrelor-treated animals had a significantly smaller extent of MI than placebo-control animals (15.7 g left ventricle and 12.0 g left ventricle versus 22.8 g left ventricle, respectively). Yet, ticagrelor reduced infarct size to a significantly greater extent than clopidogrel (further 23.5% reduction; P =0.0026), an effect supported by troponin-I assessment and histopathologic analysis ( P =0.0021). Furthermore, in comparison with clopidogrel, ticagrelor significantly diminished myocardial edema by 24.5% ( P =0.004), which correlated with infarct mass ( r =0.73; P <0.001). 8-( p -Sulfophenyl)theophylline administration abolished the cardioprotective effects of ticagrelor over clopidogrel. At a molecular level, aquaporin-4 expression decreased and the expression and activation of AMP-activated protein kinase signaling and cyclooxygenase-2 increased in the ischemic myocardium of ticagrelor- versus clopidogrel-treated animals ( P <0.05). These protein changes were not observed in those animals administered the adenosine receptor blocker 8-( p -sulfophenyl)theophylline. Conclusions: Ticagrelor, beyond its antiplatelet efficacy, exerts cardioprotective effects by reducing necrotic injury and edema formation via adenosine-dependent mechanisms.

1 March 2011 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
BBBeatriz Bermudez
Beatriz Bermudez
SLSergio Lopez
Sergio Lopez
AOAlmudena Ortega-Gomez
Almudena Ortega-Gomez
LVLOURDES M VARELA
LOURDES M VARELA
YPYolanda M. Pacheco
Yolanda M. Pacheco
FMFrancisco J.G. Muriana
Francisco J.G. Muriana
Traditionally, nutrients such as fatty acids have been viewed as substrates for the generation of high-energy molecules and as precursors for the biosynthesis of macromolecules. However, accumulating data from multiple lines of evidence suggest that dietary fatty acids are linked not only to health promotion but also to disease pathogenesis. Metabolism in humans is regulated by complex hormonal signals and substrate interactions. For many years, the clinical focus has centered on a wide metabolic picture after an overnight fast. Nonetheless, the postprandial state (i.e., "the period that comprises and follows a meal") is an important one, and silent disturbances in this period are involved in the genesis of numerous pathological conditions, including atherosclerosis. In this review article, we present an overview of the evidence demonstrating the relevance of oleic acid in olive oil on different nutrition-related issues. We also discuss the impact of oleic acid in olive oil and its clinical relevance to major risk factors for cardiovascular disease in the context of the postprandial state and with regard to other dietary fatty acids.

1 March 2011 in The American Journal of Clinical Nutrition
Verified
Journal Article
Closed access
PDF file
SLSergio Lopez
Sergio Lopez
BBBeatriz Bermudez
Beatriz Bermudez
AOAlmudena Ortega-Gomez
Almudena Ortega-Gomez
LVLOURDES M VARELA
LOURDES M VARELA
YPYolanda M Pacheco
Yolanda M Pacheco
FMFrancisco Jg Muriana
Francisco Jg Muriana
Background: The nature of dietary fats and fasting concentrations of triglycerides affect postprandial hypertriglyceridemia and glucose homeostasis.